1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Anemia Partnering 2010-2015

Anemia Partnering 2010-2015

  • May 2015
  • -
  • Currentpartnering
  • -
  • 150 pages

Summary
The Anemia Partnering 2010-2015 report provides understanding and access to the anemia partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in anemia partnering deals
Top anemia deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

Description

The Anemia Partnering 2010-2015 report provides understanding and access to the anemia partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in anemia partnering deals
Top anemia deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Anemia Partnering 2010-2015 provides understanding and access to the anemia partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of anemia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors anemia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 35 links to online copies of actual anemia deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of anemia partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of anemia technologies and products.

Report scope

Anemia Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to anemia trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in anemia dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 35 anemia deals
The leading anemia deals by value since 2010

In Anemia Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Anemia Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of anemia deal trends since 2010
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 35 actual anemia deals entered into by the world’s biopharma companies since 2010
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Keywords

anemia, hematology, partnering, licensing, deals, alliances, merger and acquisition, M&A, big pharma

Table Of Contents

Anemia Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in anemia partnering

2.1. Introduction
2.2. Anemia partnering over the years
2.3. Anemia partnering by deal type
2.4. Anemia partnering industry sector
2.5. Anemia partnering by stage of development
2.6. Anemia partnering by technology type

Chapter 3 - Average deal terms for anemia

3.1 Introduction
3.2 Average deal terms for anemia
3.3 Anemia headline values with median calculation
3.4 Anemia upfront values with median calculation
3.5 Anemia milestone values with median calculation
3.6 Anemia royalty rates with median calculation

Chapter 4 - Active anemia dealmakers

4.1. Introduction
4.2 Most active anemia dealmakers
4.3. Top anemia deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity

Chapter 5 - Anemia dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type

Chapter 6 - Partnering resource center

6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Anemia partnering since 2010
Figure 2: Anemia dealmaking activity- 2010 to 2015
Figure 3: Anemia partnering by deal type since 2010
Figure 4: Anemia partnering by industry sector since 2010
Figure 5: Anemia partnering by stage of development since 2010
Figure 6: Anemia partnering by technology type since 2010
Figure 7: Anemia deals with a headline value
Figure 8: Anemia deals with upfront payment values
Figure 9: Anemia deals with milestone payments
Figure 10: Anemia deals with royalty rates, %
Figure 11: Top anemia deals by value since 2010
Figure 12: Big pharma - top 50 - anemia deals 2010 to 2015
Figure 13: Big pharma anemia deal frequency - 2010 to 2015
Figure 14: Big biotech - top 50 - anemia deals 2010 to 2015
Figure 15: Big biotech anemia deal frequency - 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Hemophilia Treatment Drugs Market: Overview Hemophilia is a rare blood disorder. Hemophilia is a combination of two Greek words that is haima (blood) and philia (affection). Hemophilia is a hereditary ...

Apheresis Market by Product, Procedure, Application, Technology - Global Forecast to 2021

Apheresis Market by Product, Procedure, Application, Technology - Global Forecast to 2021

  • $ 5650
  • Industry report
  • February 2017
  • by MarketsandMarkets

The global apheresis market is projected to reach USD 2.06 billion by 2021, at a CAGR of 7.7% during the forecast period of 2016 to 2021. Growth in this market is majorly driven by the rising prevalence ...

Epiomic Epidemiology Series: Polycythemia Vera Forecast in 27 Major Markets 2016-2026

Epiomic Epidemiology Series: Polycythemia Vera Forecast in 27 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • December 2016
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Polycythemia Vera in 27 Major Markets Polycythemia Vera (PV), also known as erythraemia, erythrocytosis, erythrocytosis megalosplenica, ...


Download Unlimited Documents from Trusted Public Sources

Blood Disease Statistics in the US

  • February 2017
    24 pages
  • Blood Disease  

    Hospital  

    Intensive Care  

  • United States  

View report >

Blood Disease Statistics in the US

  • February 2017
    10 pages
  • Blood Disease  

    Blood Supply  

  • United States  

View report >

Blood Disease Statistics in the US

  • February 2017
    8 pages
  • Blood Disease  

    Cytokine  

    Cancer  

  • United States  

View report >

Related Market Segments :

Blood Disease

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.